Indian firm seeks denial of Sovaldi patent


Domestic generic drug maker Natco Pharma Ltd asks the Indian patent office to deny Gilead's (GILD) Sovaldi patent in the country saying it is not "inventive" enough.

If the request is successful generic drug makers may launch versions of the product.

Gilead already plans to license Sovaldi to as many as four Indian generic manufacturers to allow for lower-priced sales in India and 60 developing countries.

From other sites
Comments (12)
  • moksha22
    , contributor
    Comments (54) | Send Message
     
    So much jealousy, let GILD profit from their discovery!
    They invested lots of money for the research, now they have the right to profit.
    10 Apr 2014, 09:37 AM Reply Like
  • GaryLee276
    , contributor
    Comments (151) | Send Message
     
    Sovaldi will be a good money maker for about a year. Then we will have all the other Hep C drugs.
    10 Apr 2014, 10:08 AM Reply Like
  • duhaus
    , contributor
    Comments (320) | Send Message
     
    It is the norm in 3rd world and "developing" countries to treat every economic exchange like they're at a flea market. Everything is up for haggling and dealing. Friends who work in retail often describe tourists from these places coming into their stores and trying to negotiate the retail price down as if the salesperson has the authority to do so. This is normal for them just as it's normal for us to accept and either pay the retail price, look elsewhere for a better deal or just not buy the item. My feeling is that this is more of the same. This firm in India is just not accepting the "price" (license fees) they'll have to pay to manufacture and sell Sovaldi for . . they want more. They are going to exhaust any option they have to try and get this for less than "retail" . . good luck.
    10 Apr 2014, 10:11 AM Reply Like
  • sudhanshoo
    , contributor
    Comments (5) | Send Message
     
    Would not you love to buy good stocks at bargain prices?

     

    Similarly, what is wrong in negotiating? Price is what you pay, value is what you get.

     

    Normally, people from "developing" countries would not go to a Gap store (for example) and ask for a lower price. Most people also understand the return on invested time and effort when getting a bargain. However, there is no downside to the act. Worst case, you won't get a better price at that store because the salesperson has no authority. Best case, you may get some benefit, who knows. Try it out.
    11 Apr 2014, 06:40 AM Reply Like
  • duhaus
    , contributor
    Comments (320) | Send Message
     
    Agreed sudhanshoo. My point/opinion was that it will not come to anything and my point stands.
    11 Apr 2014, 12:07 PM Reply Like
  • Simchad
    , contributor
    Comments (107) | Send Message
     
    It would be nice if gild would comment on such a lawsuit. The stock and it's shareholders are taking a nice beating this morning.
    10 Apr 2014, 10:48 AM Reply Like
  • QuiteSavvy
    , contributor
    Comments (63) | Send Message
     
    Other hep C drugs will come from others but don't forget that Gilead has a robust pipeline of next generation hep c drugs and combinations
    10 Apr 2014, 12:37 PM Reply Like
  • GaryLee276
    , contributor
    Comments (151) | Send Message
     
    GILD is a good company for sure. When the trend is up I will be back in.
    10 Apr 2014, 12:44 PM Reply Like
  • pra
    , contributor
    Comments (65) | Send Message
     
    When does price negotiations has become a "bad thing" especially in a case where the pricing is done so high that it's absurd to begin with.. the .. insurance companies, Govt's across the world (US included.. ala medicaid).. infact all partnerships are based upon price negotiations..

     

    Here's an excerpt from the latest news on GILD..
    ----------------------...
    Indian company is not alone in claiming it's not "inventive enough".. "Natco has opposed the patent on the same grounds as New York-based Initiative for Medicines, Access & Knowledge (I-MAK), arguing that Sovaldi is not "inventive" enough, the source told Reuters.

     

    I-MAK, a group of lawyers and scientists, filed an opposition in November 2013 to the grant of a patent in India on Sovaldi, chemically called sofosbuvir, saying the drug uses "old science".
    10 Apr 2014, 12:45 PM Reply Like
  • Cleatus in Cleveland
    , contributor
    Comments (38) | Send Message
     
    " Old science" with a >90% cure rate is good enough for me! Lawyer's abetted by "scientists" just want some of the money for contributing nothing.
    10 Apr 2014, 04:26 PM Reply Like
  • mebarrett2
    , contributor
    Comments (359) | Send Message
     
    This is absurd. After offering India the opportunity to produce and sell the drug at a great discount (2k USD per 3 month course) the S-Bs complain that it is not inventive enough? Curing HVC is not inventive enough? Just a bunch of tightwads that figure their profit margin may not be high enough.

     

    Sorry, this casts a bad image on Natco. Short that stock!
    11 Apr 2014, 01:45 AM Reply Like
  • GaryLee276
    , contributor
    Comments (151) | Send Message
     
    As usual. A bunch of deadbeats trying to get something for nothing.
    11 Apr 2014, 02:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs